14 results on '"Johnson, Burles Avner"'
Search Results
2. Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
3. Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
4. Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV).
5. Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts.
6. Abstract 612: Control of the Basal Molecular Subtype of Murine Bladder Cancer by Adaptive Immunity
7. Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
8. Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer.
9. Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience.
10. Abstract 970: Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature
11. Abstract 2765: The indoleamine 2,3 dioxygenase-1 pathway drives intratumoral B cell maintenance
12. Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis.
13. Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis.
14. Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.